Rationale, design, and baseline characteristics of 2 large, simple, randomized trials evaluating telmisartan, ramipril, and their combination in high-risk patients: the Ongoing Telmisartan Alone and in Combination with Ramipril Global Endpoint Trial/Telmisartan Randomized Assessment Study in ACE Intolerant Subjects with Cardiovascular Disease (ONTARGET/TRANSCEND) trials
Top Cited Papers
- 22 June 2004
- journal article
- clinical trial
- Published by Elsevier in American Heart Journal
- Vol. 148 (1), 52-61
- https://doi.org/10.1016/j.ahj.2004.03.020
Abstract
No abstract availableKeywords
This publication has 34 references indexed in Scilit:
- Effects of Blood Pressure Lowering With Perindopril and Indapamide Therapy on Dementia and Cognitive Decline in Patients With Cerebrovascular DiseaseArchives of Internal Medicine, 2003
- Two decades of progress in preventing vascular diseaseThe Lancet, 2002
- Long-term ACE-inhibitor therapy in patients with heart failure or left-ventricular dysfunction: a systematic overview of data from individual patientsThe Lancet, 2000
- Novel mechanisms linking angiotensin II and early atherogenesisJournal of the Renin-Angiotensin-Aldosterone System, 2000
- The past, present and future of hypertension management: a potential role for AT1-receptor antagonistsJournal of the Renin-Angiotensin-Aldosterone System, 2000
- Effects of an Angiotensin-Converting–Enzyme Inhibitor, Ramipril, on Cardiovascular Events in High-Risk PatientsNew England Journal of Medicine, 2000
- Trandolapril Reduces the Incidence of Atrial Fibrillation After Acute Myocardial Infarction in Patients With Left Ventricular DysfunctionCirculation, 1999
- Alternative projections of mortality and disability by cause 1990–2020: Global Burden of Disease StudyThe Lancet, 1997
- Emerging role of angiotensin-converting enzyme inhibitors in cardiac and vascular protection.Circulation, 1994
- SERUM CHOLESTEROL, BLOOD PRESSURE, AND MORTALITY: IMPLICATIONS FROM A COHORT OF 361 662 MENThe Lancet, 1986